DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > Graduate School of Biomedical Sciences > dissertation > dissertation >

Significance of psoas muscle thickness as an indicator of muscle atrophy in patients with hepatocellular carcinoma treated with sorafenib


File Description SizeFormat
ISYK1040_Yamashima.pdf295.75 kBAdobe PDFView/Open

Title: Significance of psoas muscle thickness as an indicator of muscle atrophy in patients with hepatocellular carcinoma treated with sorafenib
Other Titles: ソラフェニブ治療中の肝細胞癌患者における腸腰筋横径と予後予測
Authors: 山島, 美緒
Authors (alternative): Yamashima, Mio
Issue Date: 20-Mar-2018
Citation: Nagasaki University (長崎大学), 博士(医学) (2018-03-20)
Abstract: Sarcopenia has been reported to be associated with the prognosis of patients with liver cirrhosis and hepatocellular carcinoma (HCC). The aim of the present study was to determine whether sarcopenia was associated with the prognosis of patients with HCC treated with sorafenib. A total of 40 patients with HCC who were treated with sorafenib were evaluated. As an indicator of skeletal muscle mass, transverse psoas muscle thickness (TPMT) was measured on computed tomography images at the level of the umbilicus prior to treatment initiation and after 1‑3 months of treatment. Pre‑TPMT/height was not associated with progression‑free survival (PFS) or overall survival (OS). The change in TPMT/height prior to and following treatment was also not associated with PFS; however, the change of TPMT/height was an independent factor affecting OS (P=0.020). A total of 40 patients were divided into two groups depending on the degree of TPMT/height loss (mild and severe muscle atrophy groups). Patients with mild muscle atrophy exhibited a significantly longer OS compared with patients with severe muscle atrophy (P=0.045). Thus, the change in skeletal muscle thickness calculated as TPMT/height may be a simple predictor of survival for patients with HCC treated with sorafenib.
Description: 長崎大学学位論文 学位記番号:博(医歯薬)甲第1040号 学位授与年月日:平成30年3月20日 / Author: Mio Yamashima, Hisamitsu Miyaaki, Takuya Honda, Hidetaka Shibata, Satoshi Miuma, Naota Taura, Kazuhiko Nakao / Citation: Molecular and Clinical Oncology, 7(3), pp.449-453; 2017
Keywords: hepatocellular carcinoma / muscle atrophy / sorafenib
URI: http://hdl.handle.net/10069/38315
ISSN: 20499450
DOI: 10.3892/mco.2017.1321
Relational Links: http://hdl.handle.net/10069/38082
Rights: © 2017 Spandidos Publications
Type: Thesis or Dissertation
Text Version: ETD
Appears in Collections:dissertation

Citable URI : http://hdl.handle.net/10069/38315

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace